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Background: No head-to-head randomized controlled trials have demonstrated the superiority of one colorectal
screening modality over another in reducing colorectal cancer mortality. We conducted a pilot randomized
controlled trial of fecal occult blood testing (FOBT), optical colonoscopy (OC), and virtual colonoscopy (VC), to
inform the planning of a larger evaluative trial.
Methods: Eligible patients (aged 50 to 70) were recruited from five primary care practices in Hamilton, ON, Canada,
between March 23, 2010 and August 11, 2010, and randomized 1:1:1 in a parallel design using an automated,
centralized telephone service to either FOBT, OC, or VC. To reflect conventional practice, patients received no
additional reminders to complete their allocated screening test beyond those received in usual practice. The
primary outcome was completion of the assigned screening procedure. Results of the index test and any follow-up
investigations were ascertained at 6 months. Participants, caregivers, and outcome assessors were not blinded to
group assignment. The trial was stopped early due to lack of ongoing funding.
Results: A total of 198 participants were enrolled, of whom 67 were allocated to FOBT, 66 to OC, and 65 to VC. The
allocated screening procedure was completed by 43 (64 %) subjects allocated to FOBT (95 % confidence interval [CI],
52–75 %), 53 (80 %) subjects allocated to OC (95 % CI, 69–88 %), and 50 (77 %) subjects allocated to VC (95 % CI,
65–85 %); because the trial stopped early, we had insufficient statistical power to detect clinically relevant differences in
completion rates. During 6 months follow-up, colorectal adenomas were detected in 0 (0 %) subjects allocated to FOBT,
12 (18 %) subjects allocated to OC, and 2 (3 %) subjects allocated to VC. One subject in the OC arm had histological
evidence of high-grade dysplasia. No subjects were diagnosed with colorectal cancer.
Conclusions: In this pilot randomized controlled trial of colorectal cancer screening in a primary care setting,
64–80 % of subjects completed their allocated screening test. These findings may be of value to investigators planning
clinical trials to evaluate the effectiveness of colorectal cancer screening.
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Colorectal cancer is a leading cause of cancer death world-
wide, killing an estimated 694,000 people each year [1].
There is evidence that certain colorectal cancer screening
modalities may reduce the incidence of adenocarcinoma
and that all approaches lead to the detection of earlier
stage disease [2]. Current practice guidelines recommend
a range of options for colorectal cancer screening, includ-
ing fecal occult blood testing (FOBT), optical (endoscopic)
colonoscopy (OC) and virtual colonoscopy (VC), also
known as computed tomography colonography [3, 4].
However, these guidelines do not endorse a single best
procedure for colorectal cancer screening, primarily be-
cause there are no head-to-head randomized controlled
trials demonstrating that one screening test is more effect-
ive than another in reducing colorectal cancer mortality.
We conducted a pilot randomized controlled trial to esti-
mate the rates of completion of assigned screening proce-
dures for patients allocated to FOBT, OC, or VC in order
to inform the planning of a larger evaluative clinical trial.
Methods
Participants and setting
Patients age 50 to 70 years, identified from rosters of 5
participating family practices in the greater Hamilton re-
gion of Ontario, Canada, were eligible to participate in this
study. Patients were excluded if they: were unable to give
informed consent; had a history of colorectal cancer, aden-
omatous polyp, or inflammatory bowel disease; had
undergone sigmoidoscopy, OC, or VC within the previous
3 years; had undergone FOBT screening in the previous
year; or, if they had severe or terminal illness that would
preclude any benefit from colorectal cancer screening.
The McMaster University Faculty of Health Sciences/
Hamilton Health Sciences Research Ethics Board approved
this study (file number 09–147) and all participants gave
written informed consent.
Study procedures
Patients were first mailed a one page invitation letter on
their family physician’s letterhead to participate in a study
of colorectal cancer screening. The letter stated that colon
cancer can be cured if detected early through screening
and that patients who choose to participate in the study
would be assigned at random to receive either FOBT, OC,
or VC. Interested patients were invited to call a central
booking office to schedule an appointment with the study
nurse in order to learn more about the study. During the
appointment, the study nurse enrolled eligible patients
into the study. Patients who did not respond to the initial
mailing were contacted once more either with a mailed re-
minder or a telephone follow-up call [5].
At the time of enrolment, we randomized patients in a
1:1:1 ratio using a parallel group design to colorectalscreening with FOBT, OC, or VC. We used random vari-
able block sizes and stratified by family physician prac-
tice and family history of colorectal cancer. Family
history was obtained from an interview with the patient
at the time of enrolment by the study nurse and was de-
fined as a history of colorectal cancer or adenomatous
polyps in a first-degree relative (parent, sibling, or child)
at any age. We used an automated, centralized, telephone-
based randomization service to maintain concealment of
the computer generated allocation sequence. Patients allo-
cated to FOBT were given the test kits along with educa-
tional materials and instructions for completion at the
time of enrolment. Patients allocated to VC or OC were
booked for these procedures using the conventional book-
ing procedures for these investigations at our institution.
FOBT was performed by the patient at home using
the guaiac-based FOBT kit recommended by the pro-
vincial Ontario Colon Cancer Check screening program
(hema-screen, Immunostics Inc., Ocean, NJ, USA). Pa-
tients submitted the completed FOBT kit to a community
laboratory and test results were sent to the patient’s family
physician and the study methods center.
Patients randomized to OC took a bowel preparation
regimen the day before the procedure, consisting of: four
5 mg tablets of bisacodyl, one sachet of sodium picosul-
fate 10 mg, magnesium oxide 3.5 g, and citric acid 12 g
(Picosalax, Ferring Inc., Toronto, Ontario, Canada) dis-
solved in 150 mL of water, and drinking at least 1 L of
clear fluid. Patients took a second sodium picosulfate sa-
chet dissolved in 150 mL of water and drank at least 1 L
of clear fluid at bedtime. During the procedure, patients
received intravenous sedation with midazolam and fen-
tanyl as needed, with typical dosages of 3 mg and 100
micrograms respectively, and received continuous moni-
toring of heart rate and oxygen saturation with a pulse
oximeter. Decisions to biopsy suspicious lesions or
perform polypectomy were left to the discretion of the
endoscopist. OC examinations were performed by staff
gastroenterologists at our academic health sciences
centre who were fully licensed for independent practice
by the regulatory body in our province.
Patients randomized to VC took a bowel preparation
regimen (same regimen as the OC arm). Two hours before
VC, patients received a small volume of oral contrast,
which consisted of 20 mL of diatrizoate meglumine/dia-
trizoate sodium (Gastrografin, E-Z-EM Canada, Anjou,
Quebec, Canada) diluted in 200 mL of water to tag any re-
sidual feces in the bowel [6, 7]. Once positioned in the
computed tomography scanner, patients were given a bowel
antispasmodic, 20 mg of hyoscine butylbromide (or, if con-
traindicated, 0.1 mg of glucagon) intravenously. A mechan-
ical insufflator was used to insufflate carbon dioxide
through a rectal tube to maintain a steady pressure of 20 to
23 mmHg. Single breath-hold computed tomographs were
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the supine and prone positions (total radiation dose 200
milliamperes-seconds). Images were reviewed by radiologist
promptly to determine whether follow-up OC for polypect-
omy or biopsy was needed. According to accepted practice
at the time of the study, polyps were only reported if greater
than 6 mm in size.
Abnormalities found on any of the screening tests
were communicated to the participant’s family physician,
and decisions about the follow-up of abnormal test re-
sults were left to the discretion of the family physician.
Research staff contacted patients by telephone once at 6
months after the study intervention to ascertain whether
the patient had undergone the study intervention and to
document whether crossover to another study arm had
occurred. At 6 months follow-up, research staff also
reviewed patients’ medical records (at Hamilton Health
Sciences, where the screening OC and VC procedures
were performed, and at the participating family phys-
ician offices) to confirm the results of the index screen-
ing test and to collect data about further testing that was
done to follow-up on findings from the index screening
test. Patients, care providers, and outcome assessors
were not blinded to the study intervention.
Outcomes
The primary outcome was completion of the initial colo-
rectal screening intervention to which the patient was
allocated. In other words, FOBT was considered
complete if the patient returned the FOBT kit to the lab,
regardless of whether they underwent follow-up OC if
the FOBT test was positive. Similarly, VC was consid-
ered complete if the patient underwent the VC examin-
ation, regardless of whether they underwent follow-up
OC based on VC findings. Secondary outcomes were:
the proportion of patients who crossed over to another
arm of the study; results of the index screening test; for
patients allocated to VC, the proportion of patients who
received same or next day OC to follow-up results found
on the index VC test; and the proportion of patients in
whom colorectal adenoma or invasive carcinoma was
found at 6 months follow-up.
Sample size calculation
Using a conservative assumption that 50 % of patients in
a given arm would complete their allocated screening
test (a proportion of 50 % would yield the widest 95 %
confidence interval) we required 196 patients to be en-
rolled in each arm to estimate the proportion of patients
who complete screening with a 95 % confidence interval
of plus or minus 7 %. Therefore, we sought to enroll 200
patients in each arm. This sample size would also have
permitted detection of an absolute difference of 13 % or
more in the primary outcome between any 2 arms witha significance level of 0.05 and 80 % power. However,
the trial was stopped early due to lack of ongoing funding.
Statistical analysis
Baseline clinical characteristics, primary and secondary out-
comes are presented using descriptive statistics (i.e., mean
and standard deviation for continuous variables and pro-
portions for categorical variables). We compared the pro-
portion of patients who completed their allocated screening
test (primary outcome) across the 3 arms using a chi-
squared test. Statistical tests were 2-tailed using a signifi-
cance level of 0.05. Analyses of the primary outcome were
conducted according to the intention-to-treat principle.
Results
Study cohort
Participants were enrolled between March 23, 2010 and
August 11, 2010 after which the trial was stopped early due
to lack of funding. A total of 198 participants were enrolled,
of whom 67 were allocated to FOBT, 66 to OC, and 65 to
VC (Fig. 1). Baseline characteristics of participating patients
were similar across the three groups (Table 1).
Completion of allocated colorectal cancer screening
procedures
The allocated screening procedure was completed by 43
(64 %) subjects allocated to FOBT (95 % confidence
interval [CI], 52 % to 75 %), 53 (80 %) subjects allocated
to OC (95 % CI, 69 % to 88 %), and 50 (77 %) subjects
allocated to VC (95 % CI, 65 % to 85 %) (P = 0.08)
(Fig. 1). Non-adherence to the allocated screening pro-
cedure was due to non-completion of the test, with the
exception of 2 subjects who crossed over to another arm
(1 crossover from FOBT to OC arm; 1 crossover from VC
to OC arm). No subjects were lost to follow-up for the
primary outcome. No subjects experienced complications
of virtual or optical colonoscopy (e.g., bowel perforation).
Outcomes after colorectal cancer screening
Of the 43 subjects who underwent FOBT, 37 (86 %)
tested negative, 4 (9 %) had indeterminate results, and 2
(5 %) tested positive; 1 of the latter 2 subjects went on
to have a follow-up OC which did not reveal any polyps
or mass lesions.
Of the 55 subjects who received OC as their index
screening test (including 2 crossovers from other arms),
22 (40 %) subjects had at least one polyp, most of which
were 5 mm or less in size, and 12 subjects had at least
one colorectal adenoma, one of which had evidence of
high grade dysplasia (Table 2).
Of the 50 subjects who received VC, 8 (16 %) had at
least one polyp greater than 5 mm in size (since smaller
polyps were not reported) and 5 (10 %) underwent
follow-up OC to further investigate findings seen on VC
Fig. 1 CONSORT study flow diagram
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OC, colorectal adenomas were found in 2 subjects, none
of which had evidence of high-grade dysplasia. After VC,
follow-up OC was able be performed on the same or
next day in 3 of the 5 subjects who were referred for
follow-up OC.
In summary, at 6 months follow-up, colorectal aden-
oma(s) were detected in 0 (0 %) subjects allocated to
FOBT, 12 (18 %) subjects allocated to OC, and 2 (3 %)
subjects allocated to VC; one subject in the OC arm had
histological evidence of high-grade dysplasia. None were
diagnosed with colorectal cancer.Table 1 Baseline characteristics of study participants
Characteristics FOBT
(N = 67)
Age, years, mean (SD) 58.7 (5.4)
Female 31 (46)
Colorectal cancer in first degree relative(s) 9 (13)
Signs or symptoms
Change in bowel habit 4 (6)
Blood in stool 3 (4)
Abdominal pain 0 (0)
>10 % weight loss in past 6 months 0 (0)





Data are reported as number (percent) unless otherwise indicated. FOBT, fecal occu
*P value is for comparison of means or proportions across the 3 groups using one-wDiscussion
In this pilot, randomized controlled trial of colorectal
cancer screening, adherence to assigned colorectal can-
cer screening was 64 %, 77 %, and 80 % for patients allo-
cated to FOBT, VC, and OC, respectively. Although the
trial was stopped early, the findings may be useful to in-
vestigators planning randomized controlled trials of
colorectal cancer screening in a primary care setting.
Our findings that 20 % to 36 % of patients did not
complete their assigned screening test has several impli-
cations for a future evaluative trial. If the goal of a future
trial were to assess the effect of these colorectal cancerOptical Colonoscopy Virtual Colonoscopy P*
(N = 66) (N = 65)
58.4 (5.6) 59 (5.6) 0.77
25 (38) 38 (58) 0.06
9 (14) 8 (12) 0.97
1 (2) 1 (2) 0.23
0 (0) 1 (2) 0.18
0 (0) 0 (0) 1.00
0 (0) 0 (0) 1.00
0 (0) 0 (0) 1.00
34 (51) 29 (45) 0.63
25 (38) 30 (46)
7 (11) 6 (9)
lt blood testing
ay analysis of variance or chi-squared tests, respectively





Subjects with polyp(s)b 22 (40)
Largest polyp 5 mm or less 14
Largest polyp 6 mm to 9 mm 2
Largest polyp 10 mm or greater 4
Distribution of polyps by size, n†
5 mm or less 33
6 mm to 9 mm 3
10 mm or greater 6
Distribution of polyps by histology, n
Hyperplastic polyp 11
Tubular adenoma 8
Sessile serrated adenoma 3
Tubulovillous adenoma 1
Subjects with colorectal adenoma(s) 12 (22)c
Subjects with invasive carcinoma 0 (0)
Data are reported as number (percent) unless otherwise indicated
aincludes 53 subjects originally allocated to OC and 2 subjects who crossed
over to OC from other arms
bas visualized on OC; polyp size data missing for 2 subjects
c1 of these subjects had an adenoma with high grade dysplasia





Subjects with polyp(s)a 8 (16)
Largest polyp 6 mm to 9 mm 7
Largest polyp 10 mm or greater 1
Distribution of polyps by size, na
6 mm to 9 mm 8
10 mm or greater 1
Patients who underwent follow-up optical
colonoscopy
5 (10)
Distribution of polyps by histology, n
Sessile serrated adenoma 3
Patients with colorectal adenoma(s) 2
Patients with invasive carcinoma 0
Data are reported as number (percent) unless otherwise indicated
aOnly polyps greater than 5 mm in size were reported (see Methods)
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cacy), then our findings suggest that modification of our
study procedures and a greater commitment of re-
sources would be needed to increase adherence rates in
a future clinical trial. In contrast, if the aim of a future
trial were to evaluate the effectiveness (not efficacy) of
colorectal cancer screening under conditions more re-
flective of usual practice, as was our intent, our findings
provide useful estimates of anticipated adherence to
FOBT, VC, and VC under typical conditions, since we
did not provide any additional reminders for participants
to complete their assigned screening procedures beyond
usual booking or testing procedures. In particular, these
estimates of test completion would be necessary to in-
form sample size calculations for a larger evaluative trial
since non-completion of screening procedures would di-
lute any effect of the screening interventions on clinical
outcomes such as colorectal cancer mortality.
Our observed adherence to FOBT of 64 % is similar to
that observed in the original trials of FOBT screening
from the 1980s which documented adherence of 60 %
and 67 % [8, 9]. In our trial, adherence was lower in the
FOBT arm compared to the OC and VC arms, but the
difference was not statistically significant. Other recent
randomized controlled trials have reported data about
screening completion rates. In one trial, participation
rates were similar regardless of screening modality(30.1 % for FOBT delivered by mail, 28.1 % for FOBT
delivered by a general practitioner or screening facility,
and 28.1 % for once-only sigmoidoscopy) [10]. In an-
other clinical trial, a statistically significant difference in
participation rates of 34.2 % for fecal immunochemical
testing versus 24.6 % for optical colonoscopy was ob-
served [11]. However, participation rates in these two tri-
als are difficult to compare directly to ours since they
randomized patients identified from population regis-
tries before obtaining informed consent for participation
in the study, whereas we did not randomize patients to a
screening intervention until after they gave consent to
participate in the study. Our estimates of adherence are
most applicable to patients who respond to invitations
from their primary care physician to participate in colo-
rectal cancer screening, agree to participate in a clinical
trial, and then undergo allocated screening under usual
conditions.
Our study has some limitations. First, we did not col-
lect data from patients about the reasons why they did
not complete their allocated screening test (e.g., lack of
interest, failure of appointment booking procedures),
which could have provided additional information to im-
prove completion rates in a future trial. Second, our
study was stopped early due to lack of funding. As a re-
sult, the estimates of adherence rates are more imprecise
than we originally sought and, because of the reduced
statistical power, it is not clear whether the lower adher-
ence rate we observed for patients allocated to FOBT
compared to the VC and OC arms is a true difference.
Nonetheless, even though our estimates of adherence
rates were not as precise as we had wanted (our original
sample size would have provided 95 % confidence
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able to achieve a precision of approximately plus or
minus 10 % with our reduced sample size. Moreover, we
believe that it is important to fully report data from clin-
ical trials that are stopped early for insufficient recruit-
ment (due to lack of funding or other reasons), since the
failure to do so threatens the integrity of clinical re-
search, and since investigators have an ethical responsi-
bility to trial participants, to funders, and to the
scientific community to disseminate the findings of their
research [12]. Finally, the overall participation rate
(i.e., number of patients enrolled out of the total number
invited) in colorectal cancer screening in our study was
low (198/1,348 = 15 %). This may have been a constraint
of our randomized design in which participating patients
could not choose which screening procedure they would
get. It is possible that patients willing to be enrolled in a
clinical trial are different from those who agree to
undergo colorectal cancer screening after it is offered by
their usual care provider in routine clinical practice.Conclusions
In this pilot randomized controlled trial of colorectal can-
cer screening reflective of usual testing conditions in a pri-
mary care setting, we found that 64 % to 80 % of subjects
completed their allocated screening test. These findings
may be of value to investigators planning clinical trials to
evaluate the effectiveness of colorectal cancer screening in
primary care settings.
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